Literature DB >> 17008706

ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.

José G Guillem1, William C Wood, Jeffrey F Moley, Andrew Berchuck, Beth Y Karlan, David G Mutch, Robert F Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L Weber, Francis Giardiello, Miguel A Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit.   

Abstract

Although the etiology of solid cancers is multifactorial, with environmental and genetic factors playing a variable role, a significant portion of the burden of cancer is accounted for by a heritable component. Increasingly, the heritable component of cancer predispositions has been linked to mutations in specific genes, and clinical interventions have been formulated for mutation carriers within affected families. The primary interventions for mutations carriers for highly penetrant syndromes such as multiple endocrine neoplasias, familial adenomatous polyposis, hereditary nonpolyposis colon cancer, and hereditary breast and ovarian cancer syndromes are primarily surgical. For that reason, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) have undertaken an educational effort within the oncology community. A joint ASCO/SSO Task Force was charged with presenting an educational symposium on the surgical management of hereditary cancer syndromes at the annual ASCO and SSO meetings, resulting in an educational position article on this topic. Both the content of the symposium and the article were developed as a consensus statement by the Task Force, with the intent of summarizing the current standard of care. This article is divided into four sections addressing breast, colorectal, ovarian and endometrial cancers, and multiple endocrine neoplasia. For each, a brief introduction on the genetics and natural history of the disease is provided, followed by a detailed description of modern surgical approaches, including a description of the clinical and genetic indications and timing of prophylactic surgery, and the efficacy of prophylactic surgery when known. Although a number of recent reviews have addressed the role of genetic testing for cancer susceptibility, including the richly illustrated Cancer Genetics and Cancer Predisposition Testing curriculum by the ASCO Cancer Genetics Working Group (available through http://www.asco.org), this article focuses on the issues surrounding the why, how, and when of surgical prophylaxis for inherited forms of cancer. This is a complex process, which requires a clear understanding of the natural history of the disease and variance of penetrance, a realistic appreciation of the potential benefit and risk of a risk-reducing procedure in a potentially otherwise healthy individual, the long-term sequelae of such surgical intervention, as well as the individual patient and family's perception of surgical risk and anticipated benefit.

Entities:  

Mesh:

Year:  2006        PMID: 17008706     DOI: 10.1200/JCO.2005.04.5260

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  43 in total

1.  Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

Authors:  Larissa A Meyer; Meaghan E Anderson; Robin A Lacour; Anuj Suri; Molly S Daniels; Diana L Urbauer; Graciela M Nogueras-Gonzalez; Kathleen M Schmeler; David M Gershenson; Karen H Lu
Journal:  Obstet Gynecol       Date:  2010-05       Impact factor: 7.661

2.  Inherited colorectal cancer syndromes.

Authors:  Robert Gryfe
Journal:  Clin Colon Rectal Surg       Date:  2009-11

3.  MRI-based quantification of residual fibroglandular tissue of the breast after conservative mastectomies.

Authors:  Ramona Woitek; Georg Pfeiler; Alex Farr; Panagiotis Kapetas; Julia Furtner; Maria Bernathova; Veronika Schöpf; Paola Clauser; Maria A Marino; Katja Pinker; Pascal A Baltzer; Thomas H Helbich
Journal:  Eur J Radiol       Date:  2018-04-26       Impact factor: 3.528

Review 4.  Patient responses to genetic information: studies of patients with hereditary cancer syndromes identify issues for use of genetic testing in nephrology practice.

Authors:  Kimberly A Kaphingst; Colleen M McBride
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

5.  American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Authors:  Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 6.  Genomic era diagnosis and management of hereditary and sporadic colon cancer.

Authors:  Edward David Esplin; Michael Paul Snyder
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

8.  Extracolonic manifestations of hereditary colorectal cancer syndromes.

Authors:  Daniel A Anaya; George J Chang; Miguel A Rodriguez-Bigas
Journal:  Clin Colon Rectal Surg       Date:  2008-11

9.  A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.

Authors:  Carolyn Y Fang; Carol Cherry; Karthik Devarajan; Tianyu Li; John Malick; Mary B Daly
Journal:  Gynecol Oncol       Date:  2009-01-13       Impact factor: 5.482

Review 10.  Hereditary diffuse gastric cancer: prophylactic surgical oncology implications.

Authors:  Henry T Lynch; Edibaldo Silva; Debrah Wirtzfeld; Pamela Hebbard; Jane Lynch; David G Huntsman
Journal:  Surg Clin North Am       Date:  2008-08       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.